Financial Burden of Hepatocellular Carcinoma Screening in Patients With Cirrhosis.

ABSTRACT:

Background

The overall value of hepatocellular carcinoma screening is defined by the balance of benefits and harms. Studies have only reported physical harms with none describing financial harms.

Methods

We conducted a multicenter pragmatic randomized clinical trial of hepatocellular carcinoma screening outreach among 2872 patients with cirrhosis from March 2018 to April 2021. Patients with positive or indeterminate results and matched patients with negative results completed surveys at baseline and at follow-up measuring financial harms via Cancer Self-Administered Questionnaire and financial burden via Comprehensive Score for Financial Toxicity Functional Assessment of Chronic Illness Therapy. Univariable and multivariable longitudinal regression analyses were performed to

SUBMITTER: Narasimman M 

PROVIDER: S-EPMC12206404 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature